Peptides, proteins and antibodies

Santina Iellamo De Gennaro; Aikaterini Lalatsa

doi:10.1007/978-3-031-59478-6_19

Peptides, proteins and antibodies

Santina Iellamo De Gennaro, Aikaterini Lalatsa

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Peptide and protein therapeutics are an area of continuous market growth and able to address a growing range of clinical pathologies due to their high specificity and potency combined with low toxicity of metabolic products and minimal potential for drug–drug interactions, which make them attractive candidates for clinical development. The pharmaceutical industry is today more in need of delivery technologies either as engineering peptide prodrugs/chimeras by appending a peptide/protein domain to a therapeutic protein to target or able to bind a particular receptor combined potentially with a material strategy (nano-enabled delivery systems or devices) for delivery via non-parenteral routes. In this chapter, the strategies able to deliver peptide or protein therapeutics via controlled delivery parenteral strategies but also oral and nasal routes and their applications will be discussed.

Original language	English
Title of host publication	Fundamentals of Pharmaceutical Nanoscience
Editors	Ijeoma F. Uchegbu, Andreas G. Schatzlein, Aikaterini Lalatsa, Dolores R. Serrano
Place of Publication	New York, NY
Chapter	19
Pages	511-654
Edition	2nd
ISBN (Electronic)	978-3-031-59478-6
DOIs	https://doi.org/10.1007/978-3-031-59478-6_19
Publication status	Published - 10 Nov 2024

Keywords

peptides
proteins
antibodies
peptide Nanofibers
pegylation
glycosylation
nanomedicines

Access to Document

10.1007/978-3-031-59478-6_19

Embargoed Document

de-Gennaro-Lalatsa-FPN-2023-Peptides-proteins-and-antibodies
Accepted author manuscript, 1.97 MB
Licence: Strath_1
Embargo ends: 10/11/25

4 Chapter

Active targeting of nanomedicines
Serrano, D. R., Kara, A., Ramirez, B. I., Ramirez, I. O., Ongoren, B. & Lalatsa, A., 10 Nov 2024, Fundamentals of Pharmaceutical Nanoscience. Uchegbu, I. F., Schatzlein, A. G., Lalatsa, A. & Serrano, D. R. (eds.). 2nd ed. New York, NY, p. 337-385
Research output: Chapter in Book/Report/Conference proceeding › Chapter
Nanomedicines for delivery across the blood-brain barrier
Lalatsa, A., Das, D. & Osouli-Bostanabad, K., 10 Nov 2024, Fundamentals of Pharmaceutical Nanoscience. Uchegbu, I. F., Schatzlein, A. G., Lalatsa, A. & Serrano Lopez, D. R. (eds.). 2nd ed. New York, p. 241-294
Research output: Chapter in Book/Report/Conference proceeding › Chapter
Nanotechnology and hydrophobic drug solubilisation
Dymock, L. & Hoskins, C., 10 Nov 2024, Fundamentals of Pharmaceutical Nanoscience. Uchegbu, I. F., Schätzlein, A. G., Lalatsa, A. & Remedios Serrano Lopez, D. (eds.). Springer Nature Switzerland AG, p. 313-335
Research output: Chapter in Book/Report/Conference proceeding › Chapter

Cite this

@inbook{b1aaafd138674573913a95c36504ee55,

title = "Peptides, proteins and antibodies",

abstract = "Peptide and protein therapeutics are an area of continuous market growth and able to address a growing range of clinical pathologies due to their high specificity and potency combined with low toxicity of metabolic products and minimal potential for drug–drug interactions, which make them attractive candidates for clinical development. The pharmaceutical industry is today more in need of delivery technologies either as engineering peptide prodrugs/chimeras by appending a peptide/protein domain to a therapeutic protein to target or able to bind a particular receptor combined potentially with a material strategy (nano-enabled delivery systems or devices) for delivery via non-parenteral routes. In this chapter, the strategies able to deliver peptide or protein therapeutics via controlled delivery parenteral strategies but also oral and nasal routes and their applications will be discussed. ",

keywords = "peptides, proteins, antibodies, peptide Nanofibers, pegylation, glycosylation, nanomedicines",

author = "{Iellamo De Gennaro}, Santina and Aikaterini Lalatsa",

year = "2024",

month = nov,

day = "10",

doi = "10.1007/978-3-031-59478-6_19",

language = "English",

isbn = "9783031594779",

pages = "511--654",

editor = "Uchegbu, {Ijeoma F.} and Schatzlein, {Andreas G.} and Lalatsa, {Aikaterini } and Serrano, {Dolores R.}",

booktitle = "Fundamentals of Pharmaceutical Nanoscience",

edition = "2nd",

}

TY - CHAP

T1 - Peptides, proteins and antibodies

AU - Iellamo De Gennaro, Santina

AU - Lalatsa, Aikaterini

PY - 2024/11/10

Y1 - 2024/11/10

N2 - Peptide and protein therapeutics are an area of continuous market growth and able to address a growing range of clinical pathologies due to their high specificity and potency combined with low toxicity of metabolic products and minimal potential for drug–drug interactions, which make them attractive candidates for clinical development. The pharmaceutical industry is today more in need of delivery technologies either as engineering peptide prodrugs/chimeras by appending a peptide/protein domain to a therapeutic protein to target or able to bind a particular receptor combined potentially with a material strategy (nano-enabled delivery systems or devices) for delivery via non-parenteral routes. In this chapter, the strategies able to deliver peptide or protein therapeutics via controlled delivery parenteral strategies but also oral and nasal routes and their applications will be discussed.

AB - Peptide and protein therapeutics are an area of continuous market growth and able to address a growing range of clinical pathologies due to their high specificity and potency combined with low toxicity of metabolic products and minimal potential for drug–drug interactions, which make them attractive candidates for clinical development. The pharmaceutical industry is today more in need of delivery technologies either as engineering peptide prodrugs/chimeras by appending a peptide/protein domain to a therapeutic protein to target or able to bind a particular receptor combined potentially with a material strategy (nano-enabled delivery systems or devices) for delivery via non-parenteral routes. In this chapter, the strategies able to deliver peptide or protein therapeutics via controlled delivery parenteral strategies but also oral and nasal routes and their applications will be discussed.

KW - peptides

KW - proteins

KW - antibodies

KW - peptide Nanofibers

KW - pegylation

KW - glycosylation

KW - nanomedicines

U2 - 10.1007/978-3-031-59478-6_19

DO - 10.1007/978-3-031-59478-6_19

M3 - Chapter

SN - 9783031594779

SP - 511

EP - 654

BT - Fundamentals of Pharmaceutical Nanoscience

A2 - Uchegbu, Ijeoma F.

A2 - Schatzlein, Andreas G.

A2 - Lalatsa, Aikaterini

A2 - Serrano, Dolores R.

CY - New York, NY

ER -

Peptides, proteins and antibodies

Abstract

Keywords

Access to Document

Embargoed Document

Fingerprint

Research output

Active targeting of nanomedicines

Nanomedicines for delivery across the blood-brain barrier

Nanotechnology and hydrophobic drug solubilisation

Cite this